What is the ticker symbol for Fulcrum Therapeutics?

Fulcrum Therapeutics trades under the ticker FULC on NASDAQ.

What sector does Fulcrum Therapeutics operate in?

Fulcrum Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze FULC in a portfolio?

PortView shows FULC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Fulcrum Therapeutics (FULC) Stock Analysis

NASDAQHealthcareBiotechnology

$3.85-0.52%

1-year price historyRange $3.14 – $14.60

52-week range$3.85

$2.83$15.74

What Fulcrum Therapeutics does

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Key metrics

Market cap

$293.74M

P/E (TTM)

-3.56

EPS (TTM)

$-1.08

Beta

3.00

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$3.74

200-day avg

$7.41

52-week high

$15.74

52-week low

$2.83

CEO

Alexander C. Sapir

ETFs linked to FULC

Broad-market and Healthcare sector ETFs an investor holding Fulcrum Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how FULC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze FULC in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Fulcrum Therapeutics?: Fulcrum Therapeutics trades under the ticker FULC on NASDAQ.
Which exchange is FULC listed on?: FULC is listed on NASDAQ.
What sector does Fulcrum Therapeutics operate in?: Fulcrum Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze FULC in a portfolio?: PortView shows FULC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.